Continued support for an interdisciplinary Pharmacology Graduate Training Program, currently in its 29th year, is proposed to prepare students for productive careers in disciplines where fundamental knowledge of quantitative and systems pharmacology is required. Alumni from this training program have gone on to academia, industry, regulatory science and consulting, to name a few of the variety of opportunities training in pharmacology provides. Our Predoctoral Training Program trains Pharmacology Graduate Group (PGG) students in classic principles of pharmacology including pharmacokinetics, dynamics, drug- receptor interactions as well as the newly emerging fields of proteomics and metabalomics. The PGG is supported by an interdepartmental group of 71 faculty from 20 departments in 4 Schools of the University of Pennsylvania. The Office of Biomedical Graduate Studies (BGS) ensures curricular development, quality control and uniform admission standards across all Graduate Groups, including PGG. Direct management of the Pharmacology Training Program is done by a five-person Advisory Committee that, in corrdination with the Executive Committee of the PGG, defines and reviews policy and selects trainees. Pharmacology Training Grant Faculty membership is governed by three criteria: (1) expertise in a relevant field of study, (2) significant contribution to training, and (3) extramura funding to support trainees. Admission of students to Graduate Programs is a tiered decision, first by the PGG, then by a BGS-wide admissions committee. Subsequent apppointment to the pharmacology training grant is decided by its Advisory Committee. Support for each trainee will encompass their first 12-24 months in thesis lab. Trainees must re-apply after the first 12 months and while most students are re- appointed for a second 12-month period, this intermediate evaluation enhances progress and productivity. Prior to appointment, students must successfully complete required courses in Cell and Molecular Biology, Fundamentals of Pharmacology and Medical pharmacology and Human physiology. Coursework extends over 1.5-2 years plus three lab rotations. All students will take a yearly course on the responsible conduct of scientific research. Students will also receive training through seminars, journal clubs, annual retreats, scientific meetings, oral and poster presentations, and social events that encourage interactions. Successful completion of a comprehensive """"""""Candidacy"""""""" examination marks the start of independent research toward the dissertation. Thesis research is conducted under the supervision of a faculty advisor and is monitored by a thesis committee and the PGG Academic Review Committee. The dissertation defense takes place when the thesis advisor and committee concur that the body of work is complete. Based on the number of potential trainees, we request support for 12 predoctoral trainees/year for the next 5 years.

Public Health Relevance

This Predoctoral Pharmacology Training Program includes education and research opportunities to provide a multifaceted doctoral program that incorporates cutting-edge research and a curriculum that provides both depth and breadth in many areas of Pharmacology. It is designed to prepare students as leaders in pharmacological sciences in academia, government, and industry.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
2T32GM008076-30
Application #
8666265
Study Section
(TWD)
Program Officer
Okita, Richard T
Project Start
1984-07-01
Project End
2019-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
30
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Chen, Liang; Brewer, Michael D; Guo, Lili et al. (2017) Enhanced Degradation of Misfolded Proteins Promotes Tumorigenesis. Cell Rep 18:3143-3154
Ruella, M; Kenderian, S S; Shestova, O et al. (2017) Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia 31:246-248
Arlauckas, Sean P; Kumar, Manoj; Popov, Anatoliy V et al. (2017) Near infrared fluorescent imaging of choline kinase alpha expression and inhibition in breast tumors. Oncotarget 8:16518-16530
Welsh, J D; Poventud-Fuentes, I; Sampietro, S et al. (2017) Hierarchical organization of the hemostatic response to penetrating injuries in the mouse macrovasculature. J Thromb Haemost 15:526-537
Shinde, Mansi Y; Sidoli, Simone; Kulej, Katarzyna et al. (2017) Phosphoproteomics reveals that glycogen synthase kinase-3 phosphorylates multiple splicing factors and is associated with alternative splicing. J Biol Chem 292:18240-18255
Ruella, Marco; Klichinsky, Michael; Kenderian, Saad S et al. (2017) Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discov 7:1154-1167
Rhoades, Seth D; Sengupta, Arjun; Weljie, Aalim M (2017) Time is ripe: maturation of metabolomics in chronobiology. Curr Opin Biotechnol 43:70-76
Yoo, Edwin J; Ojiaku, Christie A; Sunder, Krishna et al. (2017) Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches. Am J Respir Cell Mol Biol 56:700-707
Gates, Stephanie N; Yokom, Adam L; Lin, JiaBei et al. (2017) Ratchet-like polypeptide translocation mechanism of the AAA+ disaggregase Hsp104. Science 357:273-279
Gannon, Patrick J; Akay-Espinoza, Cagla; Yee, Alan C et al. (2017) HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via ?-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation. Am J Pathol 187:91-109

Showing the most recent 10 out of 109 publications